GC012F, a dual-targeting CAR-T product for BCMA/CD19 enabled by FasTCAR technology, is currently undergoing investigation in a Phase I trial conducted across multiple centers for MM in China (NCT04236011, NCT04182581, NCT04617704, NCT04935580, ChiCTR2100047061) [47]. The gene discussed is CD19; the disease is Miyoshi myopathy.